Catalyst Event
RemeGen Co Ltd (9995) · Other
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/23/2026, 12:00:00 AM
Announced that its antibody-drug conjugate (ADC) Disitamab Vedotin was approved by China's NMPA for its 4th indication: treatment of HER2-low expressing breast cancer with liver metastases; Medium importance reflects the positive regulatory milestone likely to cause >5% price impact.
Korean Translation
항체-약물 접합체(ADC) 디시타맙 베도틴이 중국 NMPA로부터 4번째 적응증인 HER2 저발현 간 전이성 유방암 치료제로 승인받음. 주요 규제 승인으로 5% 이상의 주가 영향이 예상됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM